



The use of cell secretomes opens a new era of advanced therapies

- The UAM-PEACHES Chair on cell therapies has taken place at the Autonomous University of Madrid (UAM) celebrating its 1st conference on the cellular secretome to highlight the potential of this pathway, the selective secretome, to explore new drugs in highly prevalence treatments.
- This chair announces the successful union of two investigative powers; academy with the Autonomous University of Madrid and the biopharmaceutical industry with Peaches Biotech.
- Selective secretomes are the basis that Peaches proposes as a new disruptive model for obtaining drugs. One more step towards evolution that will allow the democratization of advanced therapies which adds to the research carried out in this field by the Department of Surgery of the Faculty of Medicine of the UAM.

Madrid, June 12, 2023.-Under the title "The secretome as medicine of the 21st century", the Autonomous University of Madrid and Peaches, have started an informative cycle this Thursday that has highlighted the potential of the secretome as an approach for new treatments of pathologies of high prevalence. The meeting was attended by the country's leading experts in both clinical and regulatory areas. The therapeutic advantages of secretomes have been demonstrated and the regulatory field that has to be established for their use and distribution on a large scale has been debated.

Throughout the day, numerous studies have been presented on the behavior and function of selective secretomes that open the door to a new generation of biological drugs such as immunomodulators, anti-inflammatories and tissue regenerators that currently lack optimal treatment. In this field, Peaches has a patent built for selective secretome, called PRS; based on co-culture methods in which the communication between M2 macrophages and the different tissue cells damaged or attacked by virus bacteria is reproduced.

The secretome represents the evolution of stem cell therapies. This is the language that stem cells emit for the regeneration of damaged tissue. These cells identify their environment and provide the appropriate orders for the tissue to start the regeneration process. These chemical messages are collected, isolated and would form a new biological medicine.

In this first meeting of the UAM-PEACHES Chair, some of the advantages of secretomes over cell therapies have been shown. They are more stable than cells and can be kept cold at temperatures that are easier to handle. Important elements so that their application means a reduction in manufacturing costs, since they are much easier to use, to distribute and transport, as well as storage, making them more accessible to doctors and, consequently, to patients.

"Cellular communication is what we want to find out with this UAM-PEACHES chair or at least give a first hint of the language of the secretome and with that try to reach the hospital and the clinic so that patients benefit from these investigations," he comments. Dr. García Arranz, one of the directors of the chair. Dr. García Olmo, also director of the Chair, affirms: "thanks to the creation of this chair, a synergy arises between the University and the company PEACHES which, through clinical researchers and the UAM, will promote progress and cell therapy research.

Using the language between the immune system and the cells of different tissues, Peaches' research provides multiple therapeutic applications, such as immunomodulatory and anti-inflammatory drugs. Your PRS platform; It represents a step forward in advanced therapies and a new approach in regenerative medicine treatments, as well as cytokine storms as a reaction to infections.

In the words of the scientific director of Peaches, Dr. Pedro Lapuente: "we have made the cells talk to each other and we have understood the language of the secretomes that they emit. Now it is time to continue investigating the clinical applications that the knowledge of this cellular language gives us". The UAM-PEACHES Chair is directed by professors Damián García-Olmo and Mariano García Arranz, both with a proven track record in advanced cell therapy with stem cells.

The objective of this UAM-PEACHES Chair is the promotion of research and the dissemination of knowledge in the field of cell therapy and regenerative medicine, especially in the development of new advanced therapy treatments, based on mesenchymal stem cells and secretomes. that they emit to carry out their work of repair and regeneration. This use of selective secretomes is the basis of a new model for obtaining drugs.

For more information:

Alfonso Ortin

Director of communication

a.ortin@peaches.es

Phone: 609493127

<https://peaches.es/prensa/>

Communication team

comunicacion@peaches.es

About Peaches Biotech Group

We are focused on creating medicines based on advanced therapies, especially with secretomes, a set of cytokines obtained from the communication of stem cells with cells from different tissues, or re-education of T-lymphocytes, which will allow patients to take advantage of new therapeutic options. that will have less economic impact on the health system, will be more accessible to patients, easier to handle by clinical professionals, and break with current models.

These are the main areas of research work of the company:

PRS, Selective Rich Plasma

Process patented by Peaches Biotech, based on the secretomes of the different types of cells, a set of selective cytokines for various tissues, and which produces a regenerative and immunomodulatory effect on said tissues and their immune response. This procurement process results in a platform that has the potential to develop more than 20 different biologic drugs.

opTcells

Process based on a license from Peaches Biotech of the BIDMC patent of Harvard Medical School for the treatment of pancreatic cancer, by education of autologous T Lymphocytes, in co-culture with three-dimensional organoids generated with pancreatic tumor cells.

This cell therapy technology will be tested against other solid tumors giving rise to other

Research talent that is part of the company

Dr. Juan Carlos de Gregorio - Founder and CEO. 2005 Innovation Award IESE-Vocento-Ernst&Young Graduate in Pharmacy, Galenic specialization. FORMER CEO of Puleva Biotech.

Dr. Juan Pedro Lapuente – Scientific Director of Peaches Biotech. Doctor of Medicine, Master's Degree in Molecular and Cellular Biology from the University of Zaragoza, Master's Degree in

Transfusion and Advanced Cellular Medicine and Therapies from the University of Liège. Master in Sports Traumatology from the Catholic University of Murcia.

Dr. Manuel Hidalgo - Director of the Division of Hematology-Oncology at Weill Cornell Medicine, New York-Presbyterian. Currently, he is a Research Associate at Peaches Biotech.

Dr. Senthil Muthuswamy – Associate Professor, Department of Medicine, Harvard Medical School, Boston, Massachusetts. Director, Program in Cell Biology, Beth Israel Deaconess Medical Centre. Currently, he is a Research Associate at Peaches Biotech.